AURKA F31I polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers: A Consortium of Investigators of Modifiers of BRCA1/2 study

Cancer Epidemiology Biomarkers and Prevention

Volumn 16, Issue 7, 2007, Pages 1416-1421

  Couch, Fergus J ^a   Sinilnikova, Olga ^b   Vierkant, Robert A ^a   Pankratz, V Shane ^a   Fredericksen, Zachary S ^a   Stoppa Lyonnet, Dominique ^d   Coupier, Isabelle ^d   Hughes, David ^c   Hardouin, Agnès ^e   Berthet, Pascaline ^e   Peock, Susan ^f   Cook, Margaret ^f   Baynes, Caroline ^g   Hodgson, Shirley ^h   Morrison, Patrick J ⁱ   Porteous, Mary E ^j   Jakubowska, Anna ^k   Lubinski, Jan ^k   Gronwald, Jacek ^k   Spurdle, Amanda ^m   Chenevix Trench, Georgia ^l,m   Schmutzler, Rita ⁿ   Versmold, Beatrix ⁿ   Engel, Christoph ^o   Meindl, Alfons ^p   Sutter, Christian ^q   Horst, Jurgen ^s   Schaefer, Dieter ^t   Offit, Kenneth ^u   Kirchhoff, Tomas ^u   Andrulis, Irene L ^v,w   Ilyushik, Eduard ^v   Glendon, Gordon ^w   Devilee, Peter ^y   Vreeswijk, Maaike P G ^y   Vasen, Hans F A ^z   Borg, Ake ^aa   Backenhorn, Katja ^aa   Struewing, Jeffery P ^ab   Greene, Mark H ^ab   Neuhausen, Susan L ^ac   Rebbeck, Timothy R ^ad   Nathanson, Katherine ^ad   Domchek, Susan ^ad   Wagner, Theresa ^af   Garber, Judy E ^ag   Szabo, Csilla ^a   Zikan, Michal ^ah   Foretova, Lenka ^ai   Olson, Janet E ^a   Sellers, Thomas A ^aj   Lindor, Noralane ^a   Nevanlinna, Heli ^ak   Tommiska, Johanna ^ak   Aittomaki, Kristiina ^ak   Hamann, Ute ^r   Rashid, Muhammad U ^r   Torres, Diana ^r   Simard, Jacques ^al   Durocher, Francine ^al   Guenard, Frederic ^al   Lynch, Henry T ^am   Isaacs, Claudine ^an   Weitzel, Jeffrey ^ao   Olopade, Olufunmilayo I ^ap   Narod, Steven ^x   Daly, Mary B ^ae   Godwin, Andrew K ^ae   Tomlinson, Gail ^aq   Easton, Douglas F ^f   Antoniou, Antonis C ^f   more..

^a Mayo Clinic   (United States)

^b HOSPICES CIVILS DE LYON   (France)

^c INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^d INSERM   (France)

^e CENTRE FRANÇOIS BACLESSE   (France)

^f UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^g UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^h ST GEORGE S HOSPITAL   (United Kingdom)

ⁱ BELFAST CITY HOSPITAL   (United Kingdom)

^j WESTERN GENERAL HOSPITAL   (United Kingdom)

^k POMERANIAN MEDICAL UNIVERSITY   (Poland)

^l QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^m PETER MACCALLUM CANCER CENTRE   (Australia)

ⁿ UNIVERSITY OF COLOGNE   (Germany)

^o UNIVERSITY OF LEIPZIG   (Germany)

^p TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^q UNIVERSITY OF HEIDELBERG   (Germany)

^r GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^s UNIVERSITY OF MÜNSTER   (Germany)

^t GOETHE UNIVERSITY   (Germany)

^u MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^v MOUNT SINAI HOSPITAL   (Canada)

^w CANCER CARE ONTARIO   (Canada)

^x UNIVERSITY OF TORONTO   (Canada)

^y LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^z Dutch Foundation for the Detection of Hereditary Tumors   (Netherlands)

^aa LUND UNIVERSITY HOSPITAL   (Sweden)

^ab NATIONAL CANCER INSTITUTE   (United States)

^ac UNIVERSITY OF CALIFORNIA   (United States)

^ad UNIVERSITY OF PENNSYLVANIA   (United States)

^ae FOX CHASE CANCER CENTER   (United States)

^af MEDICAL UNIVERSITY OF VIENNA   (Austria)

^ag DANA FARBER CANCER INSTITUTE   (United States)

^ah CHARLES UNIVERSITY   (Czech Republic)

^ai MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

^aj H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^ak HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^al LAVAL UNIVERSITY   (Canada)

^am CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^an GEORGETOWN UNIVERSITY   (United States)

^ao CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^ap UNIVERSITY OF CHICAGO   (United States)

^aq UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AURORA A KINASE; BRCA1 PROTEIN; BRCA2 PROTEIN;

ADULT; ARTICLE; BREAST CANCER; CANCER RISK; CONFIDENCE INTERVAL; DNA POLYMORPHISM; FEMALE; GENE MUTATION; GENOTYPE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR;

EID: 34447498739     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-07-0129     Document Type: Article

References (19)

1. Ewart-Toland A, Briassouli P, de Koning JP, et al. Identification of Stk6/STK15 as a candidate low-penetrance tumor-susceptibility gene in mouse and human. Nat Genet 2003;34:403-12.
2. Zhang D, Hirota T, Marumoto T, et al. Cre-loxP-controlled periodic Aurora-A overexpression induces mitotic abnormalities and hyperplasia in mammary glands of mouse models. Oncogene 2004;23:8720-30.
3. Egan KM, Newcomb PA, Ambrosone CB, et al. STK15 polymorphism and breast cancer risk in a population-based study. Carcinogenesis 2004;25:2149-53.
4. Sun T, Miao X, Wang J, et al. Functional Phe31Ile polymorphism in Aurora A and risk of breast carcinoma. Carcinogenesis 2004;25:2225-30.
5. Lo YL, Yu JC, Chen ST, et al. Breast cancer risk associated with genotypic polymorphism of the mitosis-regulating gene Aurora-A/STK15/BTAK. Int J Cancer 2005;115:276-83.
6. Ewart-Toland A, Dai Q, Gao YT, et al. Aurora-A/STK15 T+91A is a general low penetrance cancer susceptibility gene: a meta-analysis of multiple cancer types. Carcinogenesis 2005;26:1368-73.
7. Cox DG, Hankinson SE, Hunter DJ. Polymorphisms of the AURKA (STK15/Aurora kinase) gene and breast cancer risk (United States). Cancer Causes Control 2006;17:81-3.
8. Dai Q, Cai QY, Shu XO, et al. Synergistic effects of STK15 gene polymorphisms and endogenous estrogen exposure in the risk of breast cancer. Cancer Epidemiol Biomarkers Prev 2004;13:2065-70.
9. Fletcher O, Johnson N, Palles C, et al. Inconsistent association between the STK15 F31I genetic polymorphism and breast cancer risk. J Natl Cancer Inst 2006;98:1014-8.
10. 2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells. Mol Cell 1999;3:389-95.
11. Deng CX. Roles of BRCA1 in centrosome duplication. Oncogene 2002;21:6222-7.
12. Wu K, Hinson SR, Ohashi A, et al. Functional evaluation and cancer risk assessment of BRCA2 unclassified variants. Cancer Res 2005;65:417-26.
13. Goldgar DE, Easton DF, Deffenbaugh AM, Monteiro ANA, Tavtigian SV, Couch FJ. Integrated evaluation of DNA sequence variants of unknown clinical significance: application to BRCA1 and BRCA2. Am J Hum Genet 2004;75:535-44.
14. Chenevix-Trench G, Healey S, Lakhani S, et al. Genetic and histopathologic evaluation of BRCA1 and BRCA2 DNA sequence variants of unknown clinical significance. Cancer Res 2006;66:2019-27.
15. Korn EL, Graubard BI, Midthune D. Time-to-event analysis of longitudinal follow-up of a survey: chose of the time-scale. Am J Epidemiol 1997;145:72-80.
16. Antoniou AC, Goldgar DE, Andrieu N, et al. A weighted cohort approach for analysing factors modifying disease risks in carriers of high-risk susceptibility genes. Genet Epidemiol 2005;29:1-11.
17. Lin DY, Wei LJ. The robust inference for the Cox proportional hazards model. J Am Stat Assoc 1989;84:1074-8.
18. 2 to M transition. J Biol Chem 2004;279:19643-8.
19. Rebbeck TR, Lynch HT, Neuhausen SL, et al.;Prevention and Observation of Surgical End Points Study Group. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002;346:1616-22.